Serum Urate as a Proposed Surrogate Outcome Measure in Gout Trials: From the OMERACT Working Group.

Melanie Birger Morillon, Robin Christensen, Jasvinder A. Singh, Nicola Dalbeth, Kenneth Saag, William J. Taylor, Tuhina Neogi, Martin A. Kennedy, Birthe M. Pedersen, Geraldine M. McCarthy, Beverley Shea, Cesar Diaz-Torne, Sara K. Tedeschi, Rebecca Grainger, Abhishek Abhishek, Angelo Gaffo, Sabrina Mai Nielsen, Alexander Noerup, Lee S. Simon, Marissa LasserePeter Tugwell, Lisa K. Stamp*, for the OMERACTGout Working Group

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Serum urate (SU) is the most common primary efficacy outcome in trials of urate-lowering therapies for gout. Despite this, it is not formally considered a validated surrogate outcome. In this paper we will outline the definitions of biomarkers and surrogate outcome measures, respectively as well as the available frameworks and challenges in the assessment of the validity of serum urate as a surrogate in gout (i.e. a reasonable replacement for gout symptoms).

Original languageEnglish
JournalSeminars in Arthritis and Rheumatism
Volume51
Issue number6
Pages (from-to)1378-1385
ISSN0049-0172
DOIs
Publication statusPublished - Dec 2021

Bibliographical note

Publisher Copyright:
© 2021 Elsevier Inc.

Keywords

  • Biomarker
  • Gout
  • OMERACT
  • Patient Research Partners
  • Serum urate
  • Surrogate

Fingerprint

Dive into the research topics of 'Serum Urate as a Proposed Surrogate Outcome Measure in Gout Trials: From the OMERACT Working Group.'. Together they form a unique fingerprint.

Cite this